Patrones de prescripción del ácido acetilsalicílico

Machado‐Alba, Jorge Enrique; García, Santiago López; Calvo-Torres, L. Felipe; Bañol-Giraldo, Alejandra M.

doi:10.1016/j.rccar.2015.03.008

Cited by 4 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…14 In Colombia, only 38.6% of high-risk cardiovascular patients achieve cholesterol low density lipoprotein (LDL) goals, 15 and 32.2% of patients who routinely receive aspirin have concomitant T2DM. 16 There is no current published data from Colombia regarding the prevalence of use of medications such as aspirin or statins among individuals with T2DM. From a pharmacoepidemiological perspective, understanding the changes in the patterns of medications over time is important for evaluating the national public health interventions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018

Machado‐Duque

García

Emura-Vélez

et al. 2021

J Prim Care Community Health

Self Cite

View full text Add to dashboard Cite

Background Type 2 diabetes mellitus (T2DM) greatly increases cardiovascular risk. Primary and secondary cardiovascular prevention lead to lower cardiovascular events, improved quality of life and lower costs related to complications. Objective To estimate the proportion of patients with T2DM undergoing drug therapy for cardiovascular prevention (aspirin and statins) in Colombia and to describe the change in patterns of use between 2008 and 2018. Methods This was a cross-sectional study comparing prescriptions for aspirin and statins in 2008 and in 2018 in outpatients diagnosed with T2DM. Records were obtained from a national drug claim database. The proportion of use of cardiovascular prevention drugs and antidiabetic drugs, medications for comorbidities and sociodemographic variables were analyzed for both periods. Results In total, 26 742 patients in 2008 and 188 321 in 2018 with a diagnosis of T2DM treated with antidiabetic drugs were identified, among whom 57.5% and 44.2% received aspirin and 44.9% and 60.2% received statins, respectively. The use of high-intensity statins increased from 1.1% in 2008 to 95.2% in 2018. The probabilities of receiving drugs in 2008 and in 2018 were higher for men (OR: 1.12, 95% CI: 1.06-1.17 and OR: 1.26, 95% CI: 1.23-1.28, respectively), for those persons over 75 years of age (OR: 6.5, 95% CI: 5.3-7.9 and OR: 5.8, 95% CI: 5.4-6.2) and for those who also received clopidogrel (OR: 5.8, 95% CI: 4.4-7.6 and OR: 2.2, 95% CI: 2.1-2.4). Conclusions The use of high-intensity statins in patients with T2DM has increased significantly in the last decade, which should reduce cardiovascular events, morbidity and mortality.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018

Machado‐Duque

García

Emura-Vélez

et al. 2021

J Prim Care Community Health

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among these, 351 articles were excluded after title screening and the abstract of the 784 remaining papers was assessed. Finally, 461 publications were excluded following the eligibility criteria and thus, 323 articles that had interpretable data and fulfilled the eligibility criteria were used for data extraction…”

Section: Resultsmentioning

confidence: 99%

“…A pharmacy dispensing company (Audifarma SA) was identified in the SLR as the most commonly used database for RWE 34,42,61,63,72,73,94‐98,100‐109,111‐115,117,118,120,122‐131,134‐141,163,168,242,301,310 . It contains demographic data, diagnosis by ICD‐10, and drug dispensation records coded by the Anatomical Therapeutic Chemical (ATC) classification, which can be used to identify comorbidities, drug‐to‐drug interactions, medication errors, adverse events, and calculate adherence rates.…”

Section: Resultsmentioning

confidence: 99%

Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review

Franco¹,

Vizcaya²

2020

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…Colombia no es ajena a esta problemática; la principal causa de morbimortalidad en el país está relacionada con las complicaciones cardiovasculares, con una tasa de mortalidad estimada de 124,2 y 122,9 por cada 100.000 hombres y mujeres, respectivamente [4, 5], y con un aumento del 2,4% por año, lo que lo constituye, por lo tanto, en un problema prioritario de salud pública [6]. Lo más grave de esta situación es que en Colombia no hay cultura de antiagregación plaquetaria [7], como sí existe en la mayoría de los países desarrollados [8].…”

unclassified

Inhibidores del receptor plaquetario P2Y12. Parte 1 de 2: escenario de acción, farmacología, aplicación clínica y limitaciones de su uso

Campuzano-Maya¹

2017

Med. Lab.

View full text Add to dashboard Cite

Las enfermedades cardiovasculares, incluidas las afecciones del corazón, del cerebro y de los vasos sanguíneos en general, representan la primera causa de muerte a nivel mundial, con diecisiete millones y medio de muertes cada año. La prevención primaria y secundaria de las enfermedades aterotrombóticas, como el infarto agudo de miocardio, el accidente cerebrovascular y las enfermedades trombóticas, además de las medidas generales para el control de los factores de riesgo tales como la obesidad, el sedentarismo, el tabaquismo, la hipertensión arterial y la diabetes, se han centrado en el control de la agregación plaquetaria. El antiagregante plaquetario por excelencia o universal, sobre todo en la prevención primaria, es la aspirina y la terapia dual con la combinación de aspirina y un inhibidor del receptor plaquetario P2Y12, principalmente el clopidogrel, es usada en la prevención secundaria y en los casos de resistencia a la aspirina. En el momento, se dispone para uso clínico de seis inhibidores del receptor plaquetario P2Y12: la ticlopidina, el clopidogrel, el prasugrel, el ticagrelor, el cangrelor y el elinogrel. En este primer módulo, de dos que serán presentados, se abordará el uso de los inhibidores del receptor plaquetario P2Y12 en la práctica del día a día en la prevención primaria y secundaria de las enfermedades aterotrombóticas, enfocado en el análisis del papel de las plaquetas en la fisiopatología de la enfermedad aterotrombótica y la descripción de los seis inhibidores del receptor plaquetario P2Y12 disponibles ahora y en el futuro. En un segundo módulo se hará una aproximación al concepto de la resistencia a los inhibidores del receptor plaquetario P2Y12, su diagnóstico desde el punto de vista del laboratorio y las diferentes alternativas de manejo cuando se presenta resistencia a uno de estos medicamentos.

show abstract

Patrones de prescripción del ácido acetilsalicílico

Cited by 4 publications

References 26 publications

Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018

Prevalence of the Use of Aspirin and Statins for Preventing Cardiovascular Events in the Colombian Population with Type 2 Diabetes Mellitus: Comparison of 2008 and 2018

Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review

Inhibidores del receptor plaquetario P2Y12. Parte 1 de 2: escenario de acción, farmacología, aplicación clínica y limitaciones de su uso

Contact Info

Product

Resources

About